NCT02055638View on ClinicalTrials.gov

Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

97

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Intermittent Explosive Disorder
Interventions
DRUG

SRX246

capsules

DRUG

Placebo

Trial Locations (7)

10029

Icahn School of Medicine at Mount Sinai, New York

11235

SPRI Clinical Trials, LLC, Brooklyn

30331

Atlanta Center for Medical Research, Atlanta

45040

Lindner Center of HOPE, Mason

60637

University of Chicago, Department of Psychiatry, Chicago

63368

Psychiatric Care and Research Center, O'Fallon

02903

Rhode Island Hospital, Department of Psychiatry, Providence

Sponsors
All Listed Sponsors
lead

Azevan Pharmaceuticals

INDUSTRY

NCT02055638 - Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder | Biotech Hunter | Biotech Hunter